n'-Aminooxymethylcarbonylhydrazino-d-biotin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 英文名称: n'-Aminooxymethylcarbonylhydrazino-d-biotin
• 英文别名: N'-(2-aminooxyacetyl)-5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanehydrazide
• 化学式: C₁₂H₂₁N₅O₄S
• 分子量: 331.39
• InChiKey: KYHUBFIOWQTECH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  160
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• Methods and compositions for detecting hematopoietic and lymphoid tissue cancer cells
  申请人：WAYNE STATE UNIVERSITY

  公开号：US10905658B2

  公开（公告）日：2021-02-02

  A method for killing hematopoietic and/or lymphoid tissue cancer cells is provided. The method includes a step identifying a subject having hematopoietic and/or lymphoid tissue cancer with circulating cells or DNA containing elevated levels of uracils and AP sites. The hematopoietic and/or lymphoid tissue cancer cells are contacted (i.e., treated) with an alkoxyamino compound having formula I: wherein: E is R1, R2, R3, R4, R5 are each independently hydrogen (H), C1-6 alkyl, F, Cl, or Br; and n is 1 to 5.

  提供了一种杀死造血和/或淋巴组织癌细胞的方法。该方法包括一个步骤，即鉴定患有造血和/或淋巴组织癌的受试者，其循环细胞或 DNA 含有较高水平的尿嘧啶和 AP 位点。造血和/或淋巴组织癌细胞与具有式 I 的烷氧基氨基化合物接触（即处理）： 其中 E 是 R1、R2、R3、R4、R5 各自独立地为氢（H）、C1-6 烷基、F、Cl 或 Br；且 n 为 1 至 5。
• Functionalization and purification of molecules by reversible group exchange
  申请人：Illumina, Inc.

  公开号：US11021504B2

  公开（公告）日：2021-06-01

  Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags.

  本公开的实施方案包括用官能团（包括在亲和方法中有用的聚组氨酸标签）使分子（如寡核苷酸）官能化的方法和组合物。一些实施方案包括通过交换功能标签来修饰和纯化复杂分子混合物的方法。
• SELECTIVE KILLING OF TUMORS OF THE HEMATOPOIETIC AND LYMPHOID TISSUES
  申请人：WAYNE STATE UNIVERSITY

  公开号：US20190022032A1

  公开（公告）日：2019-01-24

  A method for killing hematopoietic and/or lymphoid tissue cancer cells is provided. The method includes a step identifying a subject having hematopoietic and/or lymphoid tissue cancer with circulating cells or DNA containing elevated levels of uracils and AP sites. The hematopoietic and/or lymphoid tissue cancer cells are contacted (i.e., treated) with an alkoxyamino compound having formula I: wherein: E is R 1 , R 2 , R 3 , R 4 , R 5 are each independently hydrogen (H), C 1-6 alkyl, F, Cl, or Br; and n is 1 to 5.